Saturday 17 October 2026 Export HIMS’s income statement to Excel — free account

Hims & Hers Health, Inc.

HIMS Healthcare Drug Manufacturers Specialty & Generic

Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024. In the quarter to June 2026, revenue grew 38.3%, EPS fell 294.7%, free cash flow grew 5.09% and total debt rose 40.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

28.07 1.31 −4.46%

Follow HIMS

Alert me

Market cap: $6.9B
P/E: 0.0×
Fwd P/E: −213×
Dividend yield: —
F-score: 4/9
Altman Z: 4.10
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.17

Total sells 19.29

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	1	—	—	—	—	—
Sell	3	6	2	2	4	4	1	6	2	3	7	2

Insider Ownership 8.57%

Capital & Financial Ratios $m

Market Cap 6,850.00

Revenue 2,578.11

Net Income (142.03)

Free Cash Flow 83.03

Net Debt 524.25

Current Ratio 0.93

Debt/Equity 4.21

P/E ratio 0.00

Fwd P/E (213.00)

P/S ratio 2.52

P/B ratio 20.07

Past 5Y EPS Growth —

This Y EPS Growth (215.55%)

Next Y EPS Growth 150.62%

Next Y revenue growth 36.65%

Next 5Y EPS Growth 10.70%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 19.04%

10-year low 10-year high

P/B against its own 10 years 79.79%

10-year low 10-year high

EV/Sales against its own 10 years 35.74%

10-year low 10-year high

EV/FCF against its own 10 years 79.35%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	221	300	577	841
Receivables	—	—	—	375
Inventory	22	64	80	88
Other	—	—	—	—
	265	396	768	1,385

	2023	2024	2025	Q'26
Payables	43	91	143	501
ST’ Debt	—	—	—	—
Other	7	—	4	619
	88	221	404	1,483

Compound Annual Growth %

	10y	5y	3y
Sales	—	73.63%	64.55%
Cash Flow	0.00%	0.00%	0.00%
Earnings	35.73%	0.00%	0.00%
Book Value	11.25%	0.00%	20.17%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	608	753	—	—	—
’25	586	545	599	618	2,348
’24	278	316	402	481	1,477
’23	191	208	227	247	872
’22	101	114	145	167	527
’21	52	61	74	85	272
’20	30	36	41	41	149

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	89	(36)	—	—	—
’25	109	(19)	149	61	300
’24	26	54	85	86	251
’23	9	17	25	22	73
’22	(19)	(6)	6	(7)	(27)
’21	(16)	1	(16)	(3)	(34)
’20	(5)	0	3	0	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	60	(62)	—	—	—
’25	54	(65)	83	2	74
’24	15	50	82	62	209
’23	9	12	22	13	56
’22	(20)	(7)	5	(8)	(29)
’22	—	—	—	—	(27)
’21	(16)	1	(16)	(4)	(35)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.40)	(0.37)	—	—	—
’25	0.20	0.17	0.06	0.08	0.51
’24	0.05	0.06	0.32	0.11	0.53
’23	(0.05)	(0.03)	(0.04)	0.01	(0.11)
’22	(0.08)	(0.10)	(0.09)	(0.05)	(0.32)
’21	(0.34)	(0.05)	(0.08)	(0.15)	(0.58)
’20	(0.17)	(0.03)	(0.16)	(0.15)	(0.51)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	9.78	9.40	5.47	2.72	5.65	8.09	23.97	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	9.95	16.36	25.40	7.45	12.34	35.02	72.98
People
People	Employees	—	—	—	4	181	398	651	1,046	1,637	2,442
	Revenue/emp, $m	—	—	—	20.64	0.82	0.68	0.81	0.83	0.90	0.96
Income, $m
Income, $m	Revenue	—	—	—	83	149	272	527	872	1,477	2,348
	Gross margin, %	—	—	—	54.03	73.58	75.22	77.57	81.99	79.45	73.84
	EBT	—	—	—	(72)	(18)	(111)	(66)	(22)	72	124
	EBT margin, %	—	—	—	(87.18)	(12.09)	(40.75)	(12.47)	(2.47)	4.86	5.28
	Net income	—	0	0	(72)	(18)	(108)	(66)	(24)	126	128
	Depreciation	—	—	—	0	2	6	8	4	13	57
Per share, $
Per share, $	Revenue	—	—	—	2.38	4.21	1.46	2.58	4.17	6.84	10.44
	Earnings	—	—	—	(2.07)	(0.51)	(0.58)	(0.32)	(0.11)	0.58	0.57
	Cash flow	—	—	—	(2.15)	(0.07)	(0.18)	(0.13)	0.35	1.16	1.33
	Capex	—	—	—	(0.01)	(0.05)	0.00	(0.01)	(0.08)	(0.19)	(1.00)
	Free cash flow	—	—	—	(2.16)	(0.12)	(0.19)	(0.14)	0.27	0.97	0.33
	Book value	—	—	—	0.14	(4.15)	1.79	1.52	1.64	2.21	2.40
	Shares, m	—	—	—	35	35	187	205	209	216	225
Valuation, ×
Valuation, ×	P/E	—	—	—	198.00	0.00	0.00	0.00	0.00	41.69	56.96
	P/S	—	—	—	0.00	3.47	4.50	2.45	2.31	3.54	3.11
	P/B	—	—	—	0.25	0.00	3.66	4.15	5.87	10.95	13.50
	EV/Sales	—	—	—	0.00	2.80	3.61	2.12	2.06	3.33	3.28
	EV/FCF	—	—	—	0.00	(98.66)	(27.81)	(38.18)	31.99	23.51	104.10
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(75)	(2)	(34)	(27)	73	251	300
	Capex	—	—	—	0	(2)	(1)	(3)	(17)	(42)	(226)
	Free cash flow	—	—	—	(75)	(4)	(35)	(29)	56	209	74
Balance, $m
Balance, $m	Working capital	—	—	—	1	98	191	169	177	174	363
	Total debt	—	—	—	—	—	4	4	—	—	973
	Net debt	—	—	—	(2)	(100)	(247)	(180)	(221)	(300)	395
	Shareholders’ equity	—	—	—	5	(147)	335	312	344	477	541
Returns, %
Returns, %	ROA	—	—	0.00	(70.39)	(11.20)	(39.93)	(16.69)	(5.83)	21.94	8.97
	ROIC	—	—	—	(1,332.74)	0.00	(82.32)	(32.50)	(14.96)	21.92	7.05
	ROE	—	—	—	(75.36)	25.54	(114.69)	(20.32)	(7.18)	30.71	25.23

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ELAN Elanco Animal Health Incorporated	$11.8B	— (loss-making)	278×	+10.23% (above 0%: growing)	+450.00% (above 0%: growing)	+35.56% (above 0%: growing)	58.33%	7.97%	Compare
RDY Dr. Reddy's Laboratories Ltd	$10.7B	32.9×	24.3×	−14.44% (below 0%: shrinking)	−70.00% (below 0%: shrinking)	−143.40% (below 0%: shrinking)	46.54%	4.81%	Compare
HIMS Hims & Hers Health, Inc.	$6.9B	— (loss-making)	— (loss-making)	+38.25% (above 0%: growing)	n/m	+5.09% (above 0%: growing)	63.83%	(12.90%)
ALKS Alkermes plc	$6.7B	102×	— (loss-making)	+26.97% (above 0%: growing)	−99.43% (below 0%: shrinking)	+1.13% (above 0%: growing)	80.22%	3.70%	Compare
LNTH Lantheus Holdings, Inc.	$6.5B	23.7×	25.3×	+2.68% (above 0%: growing)	0.00%	+13.55% (above 0%: growing)	62.30%	25.82%	Compare
KNSA Kiniksa Pharmaceuticals International, plc	$6.2B	73.4×	38.7×	+55.36% (above 0%: growing)	+37.50% (above 0%: growing)	+66.63% (above 0%: growing)	90.32%	11.16%	Compare
AMRX AMNEAL PHARMACEUTICALS, INC.	$6.2B	38.4×	51.6×	+9.89% (above 0%: growing)	+157.14% (above 0%: growing)	−351.41% (below 0%: shrinking)	42.01%	16.30%	Compare
RGC Regencell Bioscience Holdings Limited	$4.7B	— (loss-making)	—	—	—	+57.15% (above 0%: growing)	0.00%	—	Compare
INDV Indivior Pharmaceuticals Inc.	$4.0B	11.2×	11.8×	+13.58% (above 0%: growing)	+580.00% (above 0%: growing)	+58.57% (above 0%: growing)	85.42%	46.36%	Compare
Median of peers	$6.4B	35.6×	32.0×	+10.23%	+37.50%	+24.56%	60.32%	11.16%

All 86 Drug Manufacturers Specialty & Generic stocks →

Hims & Hers Health, Inc. (HIMS) key facts

Strength: Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.
Hims & Hers Health, Inc. (HIMS) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, HIMS traded at $28.07, a market capitalization of $6.9 billion.
Return on equity was 25.2% and debt-to-equity 4.21.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 4.10 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.